Inhibition of EGF Signaling Protects the Diabetic Retina from Insulin-Induced Vascular Leakage  by Sugimoto, Masahiko et al.
The American Journal of Pathology, Vol. 183, No. 3, September 2013ajp.amjpathol.orgVASCULAR BIOLOGY, ATHEROSCLEROSIS, AND ENDOTHELIUM BIOLOGY
Inhibition of EGF Signaling Protects the Diabetic Retina
from Insulin-Induced Vascular Leakage
Masahiko Sugimoto,* Alecia Cutler,* Bailey Shen,y Scot E. Moss,z Sudha K. Iyengar,*x Ronald Klein,z Judah Folkman,{ and
Bela Anand-Apte*jjFrom the Department of Ophthalmology,* Cole Eye Institute, the Department of Molecular Medicine,jj Lerner Research Institute, and the Department of
Ophthalmology,y Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, Ohio; the Department of Ophthalmology and Visual Sciences,z
University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin; the Department of Epidemiology and Biostatistics,x Case Western
Reserve University, Cleveland, Ohio; and the Vascular Biology Program,{ Children’s Hospital Boston, Boston, MassachusettsAccepted for publicationC
P
hMay 14, 2013.
Address correspondence to Bela
Anand-Apte, M.B.B.S., Ph.D.,
Department of Ophthalmology,
Cole Eye Institute I3-161,
Cleveland Clinic Lerner
College of Medicine at CWRU,
Cleveland Clinic, 9500 Euclid
Avenue, Cleveland
OH 44195. E-mail: anandab@
ccf.org.opyright ª 2013 American Society for Inve
ublished by Elsevier Inc. All rights reserved
ttp://dx.doi.org/10.1016/j.ajpath.2013.05.017Diabetes mellitus is a disease with considerable morbidity and mortality worldwide. Breakdown of the
blooderetinal barrier and leakage from the retinal vasculature leads to diabetic macular edema, an
important cause of vision loss in patients with diabetes. Although epidemiologic studies and
randomized clinical trials suggest that glycemic control plays a major role in the development of
vascular complications of diabetes, insulin therapies for control of glucose metabolism cannot prevent
long-term retinal complications. The phenomenon of temporary paradoxical worsening of diabetic
macular edema after insulin treatment has been observed in a number of studies. In prospective studies
on noneinsulin-dependent (type 2) diabetes mellitus patients, a change in treatment from oral drugs
to insulin was often associated with a signiﬁcant increased risk of retinopathy progression and visual
impairment. Although insulin therapies are critical for regulation of the metabolic disease, their role in
the retina is controversial. In this study with diabetic mice, insulin treatment resulted in increased
vascular leakage apparently mediated by betacellulin and signaling via the epidermal growth factor
(EGF) receptor. In addition, treatment with EGF receptor inhibitors reduced retinal vascular leakage in
diabetic mice on insulin. These ﬁndings provide unique insight into the role of insulin signaling in
mediating retinal effects in diabetes and open new avenues for therapeutics to treat the retinal
complications of diabetes mellitus. (Am J Pathol 2013, 183: 987e995; http://dx.doi.org/10.1016/
j.ajpath.2013.05.017)Supported in part by NIH grants EY016490, CA106415, EY015638;
Howard Hughes Medical Institute Medical Student Fellowship no.
57007464 (B.S.); a Research to Prevent Blindness challenge grant;
a Foundation Fighting Blindness center grant; and a Research to Prevent
Blindness Lew R. Wasserman award (B.A.).Diabetic maculopathy, an important cause of vision loss in
patients with type 2 diabetes, is characterized by hyper-
permeability of retinal blood vessels and subsequent
formation of macular edema and hard exudates. Although
the increase in retinal vascular permeability occurs both
diffusely and in focal regions, the basic physiological
defect that causes retinal vascular leakage is unknown. The
blooderetinal barrier (BRB) isolates the retina from the
bloodstream, establishing a favorable environmental milieu
with the regulation of ionic balance, nutrient availability,
and blockage of potentially toxic molecules that allows for
optimal retinal function. The BRB consists of an inner
BRB, formed by endothelial cells lining the retinal blood
vessels and the outer BRB formed by the retinal pigment
epithelium (RPE), a layer of epithelial cells between thestigative Pathology.
.retina and the non-neuronal choroid.1,2 Disruption of the
BRB is an important feature of diabetic retinopathy.
Based on data from the Wisconsin Epidemiologic Study of
Diabetic Retinopathy (WESDR), a prospective population-
based cohort study of patients with type 1 and 2 diabetes
mellitus, the prevalence of clinically signiﬁcant macular edema
is 5.9% for type 1 and 7.5% for type 2 diabetes.3 Although
epidemiologic studies and randomized clinical trials suggest
that glycemic control plays a major role in the development of
Sugimoto et alvascular complications of diabetes,4 insulin therapies for
control of glucose metabolism may not prevent long-term
complications.5,6 Even though both laser photocoagulation
and anti-VEGF therapies have shown signiﬁcant promise in the
treatment of proliferating vessels in proliferative diabetic reti-
nopathy, diabetic macular edema (DME) appears to be more
resistant to these treatment approaches, suggesting that other
factors might contribute to this complication.We have recently
reported the potential role of betacellulin (Btc) in inducing
retinal vascular permeability in diabetes.7 Clinical trials and
other studies have determined that initiation of acute intensive
insulin therapy in patients with long-standing poor glycemic
control results in a transient worsening of diabetic reti-
nopathy.8e13 A change in treatment from oral drugs to insulin
in patients with noneinsulin-dependent (type 2) diabetes
mellitus was associated with a signiﬁcantly increased risk of
retinopathy progression and visual impairment.14e16 In addi-
tion, it has been reported that patients who undergo total
pancreatectomy for cancer develop severe diabetes because of
the complete absence of insulin but rarely if ever develop
proliferative diabetic retinopathy,17 even when they survive for
more than one or two decades. These reports led us to model
and evaluate the pathophysiological effects of insulin on the
retinal vasculature and the potential crosstalk between insulin
and Btc in the regulation of retinal vascular permeability.
Materials and Methods
Materials
Recombinant human vascular endothelial growth factor
(VEGF) was a kind gift fromGenentech (South San Francisco,
CA). Recombinant mouse Btc was from R&D Systems
(Minneapolis. MN). Goat polyclonal anti-Btc antibody (sc-
5802), goat polyclonal anti-actin antibody (sc-1615), rabbit
polyclonal antiezonula occludens-1 (antieZO-1) antibody
(sc-10804), horseradish peroxidaseeconjugated anti-goat IgG
(sc-2353), normal rabbit IgG (sc-2027), and normal goat IgG
(sc-2028) were from Santa Cruz Biotechnology (Santa Cruz,
CA). Horseradish peroxidaseeconjugated anti-rabbit IgG
antibody (NA934V) was from GE Healthcare (Chalfont
St Giles, UK). Rabbit polyclonal antiehypoxia-inducible
factor-1a (HIF-1a) antibody (NB100-449) was from Novus
Biologicals (Littleton, CO). Calbiochem rabbit polyclonal
anti-ADAM10 antibody (pc528) was from EMD Millipore
(Billerica, MA). Alexa Fluor 488 anti-goat IgG and Alexa
Fluor 594 anti-rabbit IgG were from Life Technologiese
Invitrogen (Carlsbad, CA). Two EGFR inhibitors were used:
Calbiochem AG1478 from EMD Millipore and cetuximab
(Erbitux) from Bristol-Myers Squibb (Princeton, NJ).
Animals and Experimental Diabetes or Insulin-Treated
Model
All animal studies were approved by the Institutional
Animal Care and Use Committee of the Cleveland Clinic988and conformed to current NIH guidelines (Guide for the
Care and Use of Laboratory Animals in Research, 8th
edition, 2011). The animals were cared for in accordance
with the Association for Research in Vision and Ophthal-
mology Statement for the Use of Animals in Ophthalmic
and Visual Research (http://www.arvo.org/about_arvo/
policies/statement_for_the_use_of_animals_in_ophthalmic_
and_visual_research, last accessed November 2010).
Female C57BL/6 mice, 6 to 8 weeks old, were purchased
from the Jackson Laboratory (Bar Harbor, ME). For in-
duction of diabetes, mice received three consecutive daily
injections of 55 mg/kg streptozotocin (STZ; Sigma-Aldrich,
St. Louis, MO) freshly dissolved in 10 mmol/L citrate
buffer, pH 4.5. Control nondiabetic mice received three
consecutive injections of citrate buffer alone. One week
after the ﬁrst STZ injection, blood glucose levels were
evaluated with a glucometer (One Touch Ultra Test strips
and One Touch UltraMini glucometer; LifeScan, Milpitas,
CA). Mice with blood glucose levels greater than 250 mg/
dL were deemed diabetic. The animals were then assigned
to the various treatment groups. Insulin pellets were
implanted 3 weeks after the ﬁrst STZ injection. Cetuximab
(1 mg per mouse) was administered i.p. once a week for two
consecutive weeks, with the ﬁrst dose being given 3 weeks
after the ﬁrst STZ injection. Animals were euthanized and
examined 2 weeks after the ﬁrst cetuximab dose.
Implantation of Insulin Pellets
Implantation of insulin pellets was performed as described
previously.18 In brief, mice were anesthetized with iso-
ﬂurane, and one controlled-release insulin implant (LinBit,
Sustained Release Insulin Implant; LinShin Canada Inc.,
Toronto, ON, Canada) was placed in the subcutaneous
space of their backs.
Determination of Protein Expression by Immunoblot
Analysis
Cells and mouse retina were lysed on ice for 20 minutes in
lysis buffer consisting of 1% NP-40, 50 mmol/L Tris/HCl
(pH 7.5), 150 mmol/L NaCl, and protease inhibitor cocktail
(cOmplete, Mini; Roche Applied Bioscience, Mannheim,
Germany). Lysates were clariﬁed by centrifugation at
18,363  g rpm for 10 minutes at 4C and subjected to
SDS-PAGE and Western blotting onto a nitrocellulose or
polyvinylidene diﬂuoride membrane (ﬁlter paper sandwich;
Life TechnologieseInvitrogen). Immunoreactive bands
were visualized after sequential incubation with a primary
antibody, either horseradish peroxidaseeconjugated anti-
goat or anti-rabbit antibody as a secondary antibody, and
enhanced chemiluminescence Western blotting detection
reagents (ECL Plus Western blotting detection system; GE
Healthcare) according to standard procedures. The blots
were stripped with Pierce ReStore Western blot stripping
buffer (Thermo Fisher Scientiﬁc, Rockford, IL) and thenajp.amjpathol.org - The American Journal of Pathology
EGF Signaling, Betacellulin, and DMEwere reprobed according to the manufacturer’s instructions.
Protein expression was quantiﬁed by densitometry (Quan-
tity One software, version 4.2.3; Bio-Rad Laboratories,
Hercules, CA).
Cell Culture and Immunoﬂuorescence
Human retinal pigment epithelium cells (ARPE-19; ATCC,
Manassas, VA) were grown in Dulbecco’s modiﬁed Eagle’s
medium/Ham’s F-12 medium supplemented with 10% fetal
bovine serum (HyClone; Thermo Scientiﬁc, Logan, UT), 50
units/mL penicillin, and 50 mg/mL streptomycin in a 5%
CO2eenriched atmosphere with constant humidity. Human
retinal endothelium cells (HRECs; ACBR1 181) were grown
in CSC complete medium (CSC complete medium kit;
Applied Cell Biology Research Institute, Kirkland,WA) with
10% fetal bovine serum, 50 units/mL penicillin and 50 mg/
mL streptomycin in a 5% CO2eenriched atmosphere with
constant humidity. Human Müller cells (MIO-M1) were
cultured in Dulbecco’s modiﬁed Eagle’s medium supple-
mented with 10% fetal bovine serum, 50 U/mL penicillin,
and 50 mg/mL streptomycin in a 5% CO2eenriched atmo-
sphere with constant humidity. Before each experiment, cells
were placed in serum-free medium for 24 hours.
On the day of the experiments, reagents were added at
the appropriate concentrations and times. For immuno-
ﬂuorescence micrography, cells grown at a density of 2
 104 cells/mL on 12-mm coverslips were ﬁxed in 10%
tricarboxylic acid for 10 minutes at 4C, then treated with
0.5% Triton X-100 for 15 minutes. To detect Btc, goat
polyclonal anti-Btc antibody was used as the primary
antibody, and Alexa Fluor 488 anti-goat IgG was used as
the secondary antibody. To visualize ZO-1, cells were
reacted with rabbit polyclonal antieZO-1 antibody as
a primary antibody. Alexa Fluor 594 anti-rabbit IgG was
used as a secondary antibody. For staining of parafﬁn
sections, slides were deparafﬁnized in xylene and rehy-
drated through an alcohol series. Endogenous peroxidase
was blocked by immersion in 0.3% hydrogen peroxidase
for 30 minutes. Slides were incubated with goat poly-
clonal anti-Btc antibody followed by Alexa Fluor 488
anti-goat IgG. Samples were imaged using a ﬂuorescence
microscope (BX61; Olympus, Tokyo, Japan) equipped
with a charge-coupled device monochrome camera
(Hamamatsu Photonics, Bridgewater, NJ) or using a Leica
TCS SP2 confocal microscope (Leica Microsystems,
Wetzlar Germany). Z-stacks were taken during confocal
image acquisition.
Statistical Analysis
All experiments were repeated at least three times. Data
were analyzed by one-way or two-way nonrepeated analysis
of variance followed by post hoc Bonferroni tests for
comparison among means. Statistical signiﬁcance was set at
P < 0.05. Data are expressed as means  SEM.The American Journal of Pathology - ajp.amjpathol.orgResults
Insulin Treatment Is a Predictor of Macular Edema in
Diabetes
Long-term data on the 10-year incidences of DME from the
WESDR in patients with type II diabetes on insulin was
25%, compared with 14% in those with type 2 diabetes not
using insulin.19 Although the decrease in the incidence of
DME in patients not taking insulin was attributed to the
likelihood of those patients having had a shorter duration of
diabetes or less severe hyperglycemia, results from the same
study evaluating the incidence of DME against disease
duration found an increase in DME in patients taking insulin
irrespective of disease duration. To address whether insulin
is a signiﬁcant predictor of macular edema, we analyzed the
WESDR type 2 diabetes cohort and selected subjects with
15 or more years of diabetes and deﬁned two groups:
subjects who had not taken insulin within 6 months of
diagnosis and were not currently taking insulin and subjects
who had been currently taking insulin for 10 or more
years.19 Using logistic regression analysis with prevalence
of macular edema as the dependent variable, and adjusting
for independent variables including duration of diabetes,
glycosylated hemoglobin, systolic blood pressure and
patient group, we determined that people with type 2 dia-
betes using insulin were signiﬁcantly more likely to have
macular edema (P Z 0.03; odds ratio Z 2.4; 95% conﬁ-
dence interval 1.1, 5.2).
Insulin Treatment in Diabetic Mice Leads to Increased
Retinal Vascular Permeability
To determine whether we could model the effect of insulin
on the BRB in vivo, we used a mouse model of STZ-
induced diabetes and an Evans Blue assay as described
previously.7,18 We generated four groups of mice: i) control
mice (normoglycemic); ii) control insulin-treated mice
(diabetic normoglycemic); iii) STZ-induced diabetic
mice not treated with insulin (hyperglycemic; blood
glucose >250 mg/dL); and iv) STZ-induced diabetic mice
treated with controlled-release insulin implants administered
3 weeks after STZ induction (normoglycemic; blood
glucose <200 mg/dL); and (Figure 1A).
Retinal vascular permeability was evaluated at 4 weeks
after induction of diabetes and was found to be increased
from 0.73 mL plasma  g retinal dry wt 1  hour1 in
nondiabetic mice (n Z 10) to 6.873 mL plasma  g retinal
dry wt 1  hour1 in STZ-induced diabetic mice (n Z 7)
(P < 0.0005). Diabetic mice treated with insulin implants
(n Z 5) showed a dramatic increase in retinal vascular
permeability, from 6.87 to 35.58 mL plasma  g retinal dry
wt1  hour1 (P Z 0.001) (Figure 1B). These results
suggest that increased retinal vascular permeability may not
be directly related to hyperglycemia and that intensive
insulin therapy in the presence of hyperglycemia may result989
Figure 1 Insulin treatment exacerbates retinal vascular permeability
and induces increased expression of ADAM10 and cleaved Btc in the retina.
A: Blood glucose levels in normal (Ctrl), insulin-treated (Ins), STZ-induced
diabetic (DM), and STZ-induced diabetic, insulin-treated mice (DMþIns). B:
Leakage of Evans Blue dye from mouse retinal vessels in Ctrl, DM, Ins, and
DMþIns mice was quantitated in whole-mount retinas 1 hour after perfu-
sion with the dye. C: Representative Western blots of soluble Btc, ADAM10,
and actin in retinas from Ctrl, DM, and DMþIns mice. Data are expressed as
means  SEM. n  5 mice per group. ***PZ 0.001, yP < 0.0005 analysis
of variance.
Sugimoto et alin signiﬁcant increase in BRB breakdown, which suggests
that this may be a good model for understanding the early
worsening of diabetic retinopathy observed after acute
intensive insulin therapy in type 1 diabetes patients.20e22Insulin-Induced Retinal Vascular Permeability Is
Mediated via ADAM10 and Btc
We have previously reported that the increased retinal
vascular permeability in diabetic mice is regulated by Btc and
disintegrin and metalloproteinase domain-containing protein
10 (ADAM10).7 To determine whether insulin treatment in
diabetic mice induces increased activation of ADAM10 and
Btc, we analyzed retinas from diabetic mice that were treated
or untreated with insulin, using Western blot analysis. Both
ADAM10 and soluble Btc were increased in retinal tissue
from diabetic mice on insulin, compared with diabetic mice
not treated with insulin (Figure 1C).990Btc Can Disrupt Tight Junctions in Endothelial Cells
and RPE Cells
To evaluate whether Btc can disrupt tight junctions in retinal
endothelial and pigment epithelial cells, we ﬁrst determined
which cells in the retina express Btc, using Western blot
analysis with Btc antibodies on lysates from HRECs, MIO-
M1 Müller cells, and ARPE-19 human RPE cells. Müller
cells and RPE cells expressed pro-Btc and soluble cleaved
Btc, whereas HRECs expressed predominantly soluble Btc
(Figure 2A). Immunohistochemistry with polyclonal Btc
antibodies using normal mouse retina identiﬁed strong
expression of Btc in the RPE and astrocytes (Figure 2B).
Staining with control nonspeciﬁc IgG showed no back-
ground staining.
We have previously demonstrated that Btc induces retinal
vascular leakage in vivo in mice.7 In the present study, we
evaluated the effects of Btc on the tight junctions of RPE
(Figure 2C) and endothelial cells (Figure 2D). Soluble
active Btc was added to conﬂuent ARPE-19 cells
(Figure 2C) or HRECs (Figure 2D) at doses of 1 ng or 100
ng and the effects on tight junction (ZO-1) expression were
compared with those of similar doses of VEGF. Compari-
sons were made with ZO-1 expression in control RPE cells
(Figure 2C) and HRECs (Figure 2D) exposed to PBS. Btc
disrupted tight junctions in HRECs (and to a lesser extent in
RPE cells), similar to the disruption induced by VEGF.
Although it does appear that HRECs are more sensitive to
Btc than are RPE cells in vitro, this remains to be veriﬁed
in vivo.Insulin-Mediated Disruption of Tight Junctions via
ADAM10 and Btc
To determine whether insulin can disrupt tight cell junctions
in RPE cells, we examined the expression of ZO-1 in
conﬂuent ARPE-19 cells after treatment with insulin. The
insulin treatment resulted in a disruption of ZO-1 in 24
hours, compared with control untreated cells (Figure 3B).
Western blot analysis of soluble Btc and ADAM10 in
insulin-treated cells showed an increase in both cleaved
soluble Btc and ADAM10 (Figure 3A). Interestingly,
HIF-1a was also increased with increasing doses of insulin
(Figure 3A), suggesting that insulin might activate
ADAM10, which in turn can cleave Btc to its soluble form.
To evaluate whether the increase in Btc is causative for
the breakdown of tight junctions we tested whether treat-
ment of RPE cells with Btc siRNA can rescue the insulin-
mediated disruption of tight junctions. We exposed cells
treated with insulin to Btc siRNA and then examined ZO-1
expression. No disruption of ZO-1 occurred in cells treated
with Btc siRNA (Figure 3B). In addition, Western blot
analysis of lysates from control cells (Figure 3C) and
insulin-treated cells (Figure 3D) showed a decrease in
soluble Btc protein in cells treated with Btc siRNA but noajp.amjpathol.org - The American Journal of Pathology
Figure 2 Btc can disrupt tight junctions in
retinal endothelial and pigment epithelial cells. A:
Representative immunoblots of pro-Btc and
soluble Btc (s-Btc) in HRECs, MIO-M1 human
Müller cells, and ARPE-19 human RPE cells, with
quantitation of the pro-Btc/s-Btc ratio. B: Local-
ization of Btc in normal mouse retina by immu-
nohistochemistry. C and D: Immunoﬂuorescent
ZO-1 expression in ARPE-19 cells (C) and HRECs
(D) after exposure to PBS and either Btc (1 or 100
ng) or VEGF (1 or 100 ng) for 24 hours. Data are
expressed as means  SEM. n  5 mice per group.
RPE, retinal pigment epithelium.
EGF Signaling, Betacellulin, and DMEeffect on ADAM10 protein, which suggests that ADAM10
is upstream of Btc activation.
To ascertain whether inhibiting ADAM10 has the same
effect in rescuing insulin-mediated disruption of tight
junctions, we added ADAM10 siRNA to cells that had been
treated with insulin and evaluated ZO-1 disruption. The
inhibition of ADAM10 resulted in an intact tight-junction
complex on the surface of the RPE cells (Figure 3B).
EGFR Inhibitor Can Prevent Insulin-Mediated Increase
in Retinal Vascular Permeability
EGF receptors belong to the ErbB family of tyrosine kinase
receptors and include EGFR (alias ErbB-1, HER1), ErbB-2
(alias Neu, HER2), ErbB-3 (alias HER3), and ErbB-4 (alias
HER4).23 After binding of a ligand, ErbB receptors form
homo- or heterodimers, followed by autophosphorylation of
tyrosine residues and secondary messenger recruitment. Btc
has been shown to bind and signal via all four EGF recep-
tors.24 Although the role of Btc25e34 and EGF receptor
signaling35 in pancreatic differentiation has been well
documented, its function in the retina has not been explored
in detail. We observed that insulin activated RPE cells treated
with Btc siRNA or ADAM10 siRNA showed a decrease inThe American Journal of Pathology - ajp.amjpathol.orgEGFR phosphorylation (Figure 3D), which suggests that
treatment with an EGFR inhibitor might inhibit insulin-
mediated tight-junction disruption and retinal vascular
leakage. We therefore treated cells exposed to insulin with
AG1478, a tyrosine kinase inhibitor that is speciﬁc for
EGFR. Western blot analysis after treatment with insulin and
AG1478 showed a decrease in EGFR phosphorylation,
compared with cells not exposed to AG1478 (Figure 4A).We
observed that AG1478 prevented the tight-junction break-
down induced by insulin, compared with cells exposed to
insulin but not treated with AG1478 (Figure 4B). We eval-
uated the efﬁcacy of systemic intraperitoneal administration
of cetuximab (a potent EGFR inhibitor) to inhibit retinal
vascular leakage in diabetic mice on insulin.
To determine whether EGFR inhibitors can prevent the
insulin-induced retinal vascular leakage in mice, we gener-
ated four groups of mice: i) diabetic mice without insulin and
without cetuximab treatment; ii) diabetic mice with insulin
but without cetuximab treatment; iii) diabetic mice without
insulin but with cetuximab treatment, and iv) diabetic mice
with both insulin and cetuximab treatment. Mice were treated
once a week with cetuximab, and retinal vascular leakage
was evaluated at week 4 after induction of diabetes. Retinal
vascular leakage was calculated as a percentage of vascular991
Figure 3 Inhibition of Btc can prevent insulin-
mediated disruption of tight junctions in retinal
pigment epithelial cells. A: Representative immu-
noblots of soluble Btc, ADAM10, HIF-1a, and actin
in ARPE-19 human RPE cells exposed to increasing
concentrations of insulin. B: Immunoﬂuorescent
ZO-1 expression in ARPE-19 cells exposed to insulin
in the presence or absence of ADAM10 siRNA or Btc
siRNA. Arrowheads indicate the disruption of ZO-1.
C: Representative immunoblots of soluble Btc and
ADAM10 in control ARPE-19 cells treated with Btc
siRNA or ADAM10 siRNA. D: Representative immu-
noblots of soluble Btc, ADAM10, EGFR, phosphor-
ylated EGFR (pEGFR), and actin in ARPE-19 human
RPE cells exposed to insulin (100 nmol/L) in the
presence of Btc siRNA or ADAM10 siRNA, with
quantitation of the EGFR/pEGFR ratio after no
treatment or treatment with Btc siRNA or ADAM10
siRNA. *P < 0.05. Data are expressed as means 
SEM. n  5 mice per group. NT, non-targeting
control RNA.
Sugimoto et alleakage observed in untreated diabetic mice. The increase in
retinal vascular leakage observed in diabetic mice on insulin
was dramatically reduced when diabetic mice were treated
with cetuximab (Figure 4C).Discussion
Macular edema, an important cause of vision impairment in
patients with diabetes, is a consequence of increased retinal
vascular permeability and breakdown of the BRB. Based on
the results of early randomized trials such as the UK
Prospective Diabetic Study36 and the Diabetes Control and
Complications Trial,37 which compared intensive versus
conventional therapies for hyperglycemia and showed the
effectiveness of intensive glycemic control in minimizing
the risk of developing microvascular complications, the
American Diabetes Association recommended a target of
<7% for glycosylated hemoglobin (HbA1C) for nonpreg-
nant adults in general.38 Investigators in the ACCORD Trial
found a statistically signiﬁcant increase in overall mortality
in the intensive glycemic control group, leading to early
termination of this arm of the study.39 At the same time, the
ACCORD eye study group reported that the intensive gly-
cemic control therapy signiﬁcantly reduced the risk of
progression of diabetic retinopathy but did not reduce the
risk of moderate vision loss.40 Moreover, additional
WESDR data indicated that higher amounts of exogenous
insulin are related to an increased incidence of macular
edema.41 The Epidemiology of Diabetes Interventions and
Complications study determined a higher risk for develop-
ment of complications of DR in patients on conventional
insulin therapy even 4 and 10 years after switching to992intensive insulin therapy, despite normal HbA1C levels.42,43
Our ﬁndings from the present study analyzing the WESDR
study samples and normalizing for HbA1C levels also
suggest that insulin may be correlated with the incidence of
diabetic macular edema independent of blood sugar control.
Although our data are preliminary, the ﬁndings certainly
bring into question the role of blood sugar control in the
regulation of retinal vascular leakage.
Adding to this conundrum is the observation that patients
with varying degrees of retinopathy often experience a para-
doxical worsening of their retinopathy symptoms concomi-
tant with the rapid lowering of high levels of glycemia
associated with the onset of insulin therapy to control their
hyperglycemia.8e13,44 Such worsening of diabetic retinop-
athy has been reported to be related to upregulation of
insulin-like growth factor (IGF).14,45e47 Nonetheless, the
molecular mechanisms that contribute to the early-worsening
paradox have remained elusive. Elucidation of these mech-
anisms should allow the design of therapies to prevent
symptoms of early worsening of retinopathy during insulin
therapy. An early report in 2002 suggested that acute inten-
sive insulin therapy exacerbates diabetic BRB breakdown via
hypoxia-inducible factor-1a and VEGF18; the authors used
an STZ mouse model similar to that in the present study.
The present results suggest that the association of macular
edema with insulin use may be a consequence of the effect
of Btc and EGF receptor signaling in the RPE that regulates
the outer BRB. It is conceivable that a subset of patients
may be more susceptible to these effects that result in DME.
Crosstalk between the insulin receptor and EGF receptor
signaling systems has been reported to play a role in growth
and differentiation in Drosophila melanogaster.48 The
authors found that phospholipase C-g activation by theajp.amjpathol.org - The American Journal of Pathology
Figure 4 EGFR inhibitors can prevent insulin-mediated disruption of
tight junctions in retinal pigment epithelial cells (in vitro) and retinal
vascular leakage in vivo. A: Representative immunoblots of EGFR, pEGFR,
and actin in human RPE cell line (ARPE-19) exposed to 100 nmol/L insulin
in the presence of EGFR inhibitor AG1478. B: Immunoﬂuorescent ZO-1
expression in ARPE-19 cells exposed to insulin in the presence or
absence of 1 mmol/L EGFR inhibitor AG1478. C: Leakage of Evans Blue
dye (EB) from retinal vessels of DMþcetuximab, DMþIns, and
DMþInsþcetuximab mice. The cetuximab dose was 1 mg per mouse. Evans
Blue dye leakage was quantitated in whole-mount retinas at 1 hour after
perfusion with the dye. Data are expressed as means  SEM. n  5 mice per
group. **P Z 0.01 versus DMþIns.
EGF Signaling, Betacellulin, and DME
The American Journal of Pathology - ajp.amjpathol.orginsulin pathway positively regulates EGF pathway during
cell growth and negatively regulates the same pathway
during differentiation. This implies that there may be other
factors contributing to the link between insulin and EGF
signaling pathways that may be dependent on tissue type
and or physiological homeostatic state. Insulin has also been
shown to increase the proteolytic activities of ADAM10 and
stimulate the cleavage and release of the extracellular
domain of Klotho.49 EGF and Btc are biologically important
substrates of ADAM10.50
With the present study, we have identiﬁed an additional
mechanism involving ADAM10, Btc, and signaling via the
EGF receptor for the transient BRB disruption that is
a consequence of intensive insulin therapy. In addition, we
have demonstrated that EGFR inhibitor can attenuate the
increased retinal vascular leakage after insulin therapy.
However, given the absence of speciﬁc inhibitors to the
ADAM10/Btc pathway that could be used in vivo, the role
of other pathways of EGF receptor activation that lead to
this phenomenon cannot be excluded.
Mice lacking insulin receptors or insulin-like growth
factor receptors are resistant to developing retinal neo-
vascularization.51 Insulin edema (the term was coined by
Leifer52 in 1928) refers to describe the development of
severe acute edema in insulin-treated diabetic patients.53 A
report that insulin increases the permeability of subdermal
vessels54 suggests that insulin treatment could have global
effects on vascular permeability. With the present study, we
have demonstrated that insulin can disrupt tight junctions in
RPE cells and up-regulate ADAM10 and the subsequent
soluble active Btc. That the soluble form of Btc plays a role
in the disruption of tight junctions was demonstrated by the
ability of Btc siRNA to prevent insulin-induced disruption
of tight junctions.
In diabetic mice, insulin signaling in retinal endothelial cells
is differentially regulated, relative to insulin signaling in classic
target tissues such as liver.55 In STZ-induced diabetic mice and
ob/ob mouse retinas, insulin receptor (IR) and insulin receptor
substrate-2 (IRS-2) protein and tyrosine phosphorylation were
increased by insulin.55 These ﬁndings suggest that, in the
diabetic state, there may be an increase in the tonic activity of
insulin receptor in the retina, which results in activation of
ADAM10, cleavage of Btc to its active form, disruption of
RPE and/or endothelial tight junctions, retinal vascular
leakage, and DME and diabetic retinopathy. This retinal
response may be further exacerbated with insulin therapy
leading toworsening of symptoms. Binding of insulin to the IR
receptor activates the intrinsic tyrosine kinase activity in the
b subunit, induces autophosphorylation on tyrosine residues
within its tyrosine kinase domain, and initiates a cascade of
phosphorylation events on downstream substrates that include
insulin receptor substrates (IRS-1, -2, -3, and -4), Grb-2
associated binder (Gab-1), Shc, and Cbl; these in turn recruit
other adapter and enzymatic proteins (speciﬁcally, phosphati-
dylinositol 30-OH kinase and the PI3K and Akt pathway) to
propagate signal transduction and induce a biological effect.993
Sugimoto et alAlthough insulin signaling has been extensively charac-
terized in liver, adipose tissue, and skeletal muscle, its
ability to modulate biological activity in the retina has
begun to be recognized only in the past decade.56 Retinal
insulin receptor kinase activity is equivalent to that of the
brain; it does not ﬂuctuate with the feeding/fasting cycle and
is maintained in a tonic state of activity. Although immu-
nohistochemistry studies demonstrate a signal for IR in all
layers of the retina, speciﬁc binding has been identiﬁed in
retinal endothelial cells, pericytes, and the RPE. However,
the controversy in the literature as to whether insulin
signaling is accentuated55 or attenuated57 in STZ-induced
diabetes remains unresolved. In addition, it is likely that
insulin might signal uniquely in different tissues, based on
metabolic requirements. If insulin-mediated Btc signaling is
speciﬁc to retinal tissue, then targeting the retina with
ADAM10 blockers or EGFR inhibitors offers a potentially
useful therapeutic approach to the insulin-induced retinal
vascular leakage seen in some patients with diabetes.
Conclusions
Insulin treatment of diabetes results in increased retinal
vascular permeability mediated via the Btc/ADAM10
pathway. Inhibition of EGF signaling and/or ADAM10 may
be a useful therapeutic approach in combination with insulin
to prevent retinal vascular leakage.
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